Prostate Cancer | Tumor

CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.

Prostate Cancer Survival May Be Affected By How the Body Processes Coffee, But More Research is Needed

September 27th 2022

Men with prostate cancer who were “fast metabolizers” of caffeine from coffee tended to have better prostate cancer-specific survival, according to recent research.

Why We Should Curse Cancer

September 23rd 2022

When talking about cancer, it’s OK to use profanities sometimes.

NFL Star Shannon Sharpe Shares Prostate Cancer Diagnosis, ‘Good Morning America’ Raises Awareness for Bone Marrow Transplants and More

September 23rd 2022

From NFL Hall of Famer Shannon Sharpe and Monty Python member sharing their cancer diagnoses to “Good Morning America” promoting Be The Match, here’s what’s happening in the cancer space this week.

This Prostate Cancer Awareness Month, I’m Sharing Our Experience With the Disease

September 20th 2022

When my husband was diagnosed with prostate cancer in his mid 40s, we opted for a more aggressive treatment strategy, which led him being cancer-free and able to enjoy a healthy sex life.

Longer Hormone Therapy After Main Treatments Delays Prostate Cancer Metastasis

September 13th 2022

Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.

Adding Keytruda to a Combination of Abiraterone Acetate Plus Prednisone Continues to Demonstrate Anti-Tumor Activity in a Group of Patients With Prostate Cancer

September 12th 2022

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant prostate cancer.

CAR-T Cell Therapy Shows Promise in Relapsed/Refractory Solid Cancers

September 11th 2022

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

Jane Fonda Provides a Cancer Update, Old News Clipping Helps Patient With Leukemia Benefit from the Sept. 11 Victim Fund and More

September 9th 2022

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

Cancer Made Me Appreciate the Small Things in Life

September 6th 2022

There’s a flip side to the trauma of cancer — a better appreciation of the small things in everyday life.

I’m Thankful for Early Cancer Detection

August 31st 2022

Even though I had no symptoms, my prostate cancer was caught thanks to frequent follow-ups with my doctor.

Praising My Oncologist and Nurse Publicly

August 29th 2022

I recently was asked to speak at a banquet for my cancer center and saw that as a great opportunity to recognize those who cared for me.

Football Quarterback Len Dawson Dies of Cancer, Actress Jennette McCurdy Discusses Her Mom’s Cancer in Memoir and More

August 26th 2022

From the death of a football Hall of Famer and a golf champion to actress and former Nickelodeon star Jennette McCurdy discussing her mother’s breast cancer in her memoir, “I’m Glad My Mom Died,” here’s what’s happening in the cancer space this week.

Long-Term Findings Confirm Addition of Radiotherapy to Standard of Care in Metastatic Prostate Cancer Improves Survival

August 24th 2022

Radiotherapy with standard of care for the treatment of patients with low-burden metastatic prostate cancer had minimal effects on quality of life over a five-year follow-up period.

ESPN Analyst Dick Vitale Announces He is Cancer-Free, WHO Deems Firefighting a Cancer-Causing Profession and More

August 19th 2022

From ESPN analyst Dick Vitale announcing he is cancer-free months following a lymphoma diagnosis to a Speedo-clad race in South Africa to raise awareness for cancer, here’s what’s happening in the oncology space this week.

FDA Grants Priority Review to Lynparza-Based Combination for Metastatic Prostate Cancer

August 17th 2022

If approved, the Lynparza-based regimen would become the first combination of a PARP inhibitor and a hormonal agent for metastatic castration-resistant prostate cancer.

I Use a Simple Button to Combat Anti-Maskers, Since Cancer Made Me Immunocompromised

August 16th 2022

I was shocked at a recent doctor appointment when practically nobody in the office was wearing a mask.

Unlike With Baseball, There Are No Rules When it Comes to Cancer

August 16th 2022

The rules of baseball are fair and as long as you do your best, the outcome is always desirable. But with cancer, there are no rules because cancer does what it likes and constantly changes the game.

Support and Advice for Patients with mCRPC and Their Caregivers

August 11th 2022

Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community.

Investigational Drug-Libtayo Combo Demonstrates Clinical Activity in Metastatic Prostate Cancer

August 8th 2022

Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.

Keytruda Plus Chemotherapy Is Not Superior to Chemotherapy Alone in Metastatic Prostate Cancer

August 8th 2022

Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 patients.

Follow-up and Side Effects in Patients Treated with Lutetium 177-PSMA 167

August 8th 2022

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.

FDA Approves Nubeqa Tablet Regimen for Metastatic Hormone-Sensitive Prostate Cancer

August 5th 2022

The Food and Drug Administration approved oral Nubeqa plus the chemotherapy docetaxel for patients with metastatic hormone-sensitive prostate cancer.

Primary Radiotherapy Associated With Increased Risk For Secondary Primary Cancers Among Patients With Prostate Cancer

August 3rd 2022

Treatment with primary radiotherapy was linked to an increased risk for the development of secondary primary cancers among a large group of men with localized prostate cancer, according to recent study findings.

Clinical Considerations Related to Lutetium 177– PSMA-617 Treatment in mCRPC

August 2nd 2022

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).

A Multi-Disciplinary Approach to Treatment for Patients with mCRPC

August 2nd 2022

Drs Matthew Rettig and Jeremie Calais explain what it means to be a part of a collaborative team and how communication plays a big role in patients receiving optimal treatment.

The Incredible Shrinking Patient With Cancer

August 2nd 2022

Cancer treatment-related osteoporosis caused me to shrink two inches.

Easy-to-Swallow Drug Being Investigated for Prostate Cancer Treatment

August 1st 2022

TAVT-45, an easy-to-swallow drug that can be suspended in water or juice, is being studied for the treatment of patients with metastatic prostate cancer.

Treatment Journey Shared by a Patient with mCRPC and his Caregiver

July 26th 2022

Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood.

VISION Trial of Lutetium-177-PSMA-617 in mCRPC: Clinical Implications

July 26th 2022

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).

I’ve Found a New Home With Other Cancer Survivors

July 19th 2022

As I reflect on cancer survivorship, I notice how important the camraderie with fellow survivors is.